Physician profile
Samuel H Friedman
NPI 1356363352
$2,861.20
in general payments reported to CMS, 2019-2025
21 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $613 · 2021: $327 · 2022: $287 · 2023: $346 · 2024: $243 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,244.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.66 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $207.07 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $169.92 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $122.71 | 2019-2020 | |
| Amarin Pharma, INC. | $118.93 | 2019 | |
| Amgen INC. | $107.03 | 2019-2020 | |
| Glaxosmithkline, LLC. | $97.40 | 2019-2025 | Pediarix, Rotarix, Bexsero |
| Currax Pharmaceuticals LLC | $37.01 | 2021-2023 | Contrave |
| Medtronic, INC. | $29.01 | 2022 | |
| Lilly USA, LLC | $27.31 | 2019 | |
| Companion Medical, INC. | $22.73 | 2019 | |
| Seqirus USA INC | $19.00 | 2025 | Fluad, Flucelvax |
| Echosens North America, INC. | $18.47 | 2019 | |
| Lundbeck LLC | $18.00 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $15.14 | 2019 | |
| Bardy Diagnostics, INC. | $14.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.87 | 2021 | |
| Althera Pharmaceuticals LLC | $13.14 | 2021 | |
| Astellas Pharma US INC | $12.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.